Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-1 IPO registration
- 3.1 Certificate of Incorporation of Felicitex Therapeutics Inc
- 3.2 Amended and Restated Certificate of Incorporation of Felicitex Therapeutics Inc
- 3.3 Second Amended and Restated Certificate of Incorporation of Felicitex Therapeutics Inc
- 3.4 Certificate of Amendment of Felicitex Therapeutics Inc
- 3.5 Second Certificate of Amendment of Felicitex Therapeutics Inc
- 3.6 Third Amended and Restated Certificate of Incorporation of Felicitex Therapeutics Inc
- 3.8 Bylaws of Felicitex Therapeutics Inc
- 3.9 Certificate of Merger of Tarmeta Biosciences, LLC and Felicitex Therapeutics Inc., Dated December 30, 2021
- 4.5 Warrant to Purchase Common Shares Between Felicitex Therapeutics Inc. and Marc Duey, Dated March 17, 2020
- 4.6 Warrant to Purchase Common Shares Between Felicitex Therapeutics Inc. and Marc Duey, Dated March 17, 2021
- 4.7 Warrant to Purchase Common Shares Between Felicitex Therapeutics, Inc and Marc Duey, Dated November 2, 2021
- 10.1 Agreement and Plan of Merger Between Felicitex Therapeutics Inc. and Tarmeta Biosciences, LLC, Dated December 30, 2021
- 10.2 License and Collaboration Agreement Between Felicitex Therapeutics Inc. and Diaxonhit, Dated April 16, 2014
- 10.3 Amendment No. 1 to License and Collaboration Agreement Between Felicitex Therapeutics Inc. and Diaxonhit, Dated July 21, 2014
- 10.4 Amendment No. 2 to License and Collaboration Agreement Between Felicitex Therapeutics Inc. and Eurobio Scientific Sa (Formerly Diaxonhit), Dated February 14, 2022
- 10.5 Research Collaboration and Licensing Option Agreement Between Felicitex Therapeutics Inc. and Selvita S.a., Dated November 6, 2014
- 10.6 Notice of Option Exercise Under the Research Collaboration and Option Agreement Dated October 1, 2014, Dated August 30, 2018
- 10.7 Exclusive License Agreement Between Felicitex Therapeutics Inc. and Selvita S.a., Dated December 31, 2018
- 10.8 Amendment No. 1 to Exclusive Licensing Agreement Between Felicitex Therapeutics Inc. and Selvita S.a., Dated April 16, 2019
- 10.9 Material Transfer and Royalty Agreement Between Felicitex Therapeutics Inc. and Memorial Sloan Kettering Cancer Center, Dated December 4, 2020
- 10.10 Material Transfer Agreement Between Felicitex Therapeutics Inc. and Equilibre Biopharmaceuticals, Dated February 15, 2021
- 10.11 Material Transfer Agreement Between Felicitex Therapeutics Inc. and Whitehead Institute for Biomedical Research, Dated January 29, 2020
- 10.12 Employment Agreement Between Felicitex Therapeutics Inc. and Maria Vilenchik Dated March 10, 2022
- 10.13 Employment Contract Between Felicitex Therapeutics and Alexei Belenky Dated December 30, 2021
- 10.14 Form of Independent Director Agreement Between Felicitex Therapeutics Inc. and Each Independent Director and Each Director Nominee
- 10.15 Form of Indemnification Agreement Between Felicitex Therapeutics Inc. and Each Independent Director and Each Director Nominee
- 10.16 Felicitex Therapeutics Inc. 2012 Stock Option and Restricted Stock Plan
- 10.17 Felicitex Therapeutics Non-statutory Stock Option Agreement with Valeria Povolotsky, Dated March 1, 2013
- 10.18 Felicitex Therapeutics Non-statutory Stock Option Agreement with Yuriy Gankin Dated March 1, 2013
- 10.19 Felicitex Therapeutics Non-statutory Stock Option Agreement with Michael Frid Dated March 1, 2013
- 10.20 Felicitex Therapeutics Non-statutory Stock Option Agreement with Maria Vilenchik Dated March 1, 2013
- 10.21 Felicitex Therapeutics Inc. 2022 Equity Incentive Plan
- 10.22 Shareholder Loan Agreement Between Marc Duey and Felicitex Therapeutics Inc., Dated January 16, 2018
- 10.23 Shareholder Loan Agreement Between Marc Duey and Felicitex Therapeutics Inc., Dated March 31, 2020
- 10.24 Grid Note Between Marc Duey and Felicitex Therapeutics Dated March 16, 2022
- 10.25 Grant Agreement from Massachusetts Life Sciences Center Dated July 15, 2015
- 10.26 Consulting Agreement Between Felicitex Therapeutics Inc. and Michael Frid, Dated July 20, 2012
- 10.27 Consulting Agreement Between Felicitex Therapeutics Inc. and Valeria Povolotsky, PH.D., Dated July 20, 2012
- 10.28 Lease Between Felicitex Therapeutics Inc., Tarmeta Biosciences, LLC and Kaufman Nir LLC, Dated March 15, 2017
- 10.30 Board of Directors Agreement Between Felicitex Therapeutics Inc. and Yuriy Gankin, Dated July 23, 2021
- 10.31 Board of Directors Agreement Between Felicitex Therapeutics Inc. and Valeria Povolotsky, Dated July 23, 2021
- 10.32 Board of Directors Agreement Between Felicitex Therapeutics Inc. and Michael Frid, Dated July 23, 2021
- 10.33 Board of Directors Agreement Between Felicitex Therapeutics Inc. and Alex Shlyankevich, Dated July 23, 2021
- 10.34 Board of Directors Agreement Between Felicitex Therapeutics Inc. and Marc Duey, Dated July 23, 2021
- 10.35 Board of Directors Agreement Between Felicitex Therapeutics Inc. and Maria Vilenchik, Dated July 23, 2021
- 10.36 Material Transfer and Agreement Between Felicitex Therapeutics Inc. and Uab Dolcerx Baltika, Dated May 15, 2021
- 10.37 Material Transfer and Agreement Between Felicitex Therapeutics Inc. and Barbara Ann Karmanos Cancer Institute, Dated July 18, 2022
- 14.1 Code of Ethics and Business Conduct
- 21.1 List of Subsidiaries
- 23.1 Consent of Friedman LLP
- 99.1 Audit Committee Charter
- 99.2 Compensation Committee Charter
- 99.3 Nominating and Corporate Governance Committee Charter
- 99.5 Consent of Douglas T. Moore to Be Named As a Director Nominee
- EX-FILING FEES Filing Fees Table
Associated filings
FLCT similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the inclusion in this Registration Statement on Form S-1 of our report dated March 22, 2022, except for Note 1 and Note 15, as to which the date is June 2, 2022, which includes an explanatory paragraph as to the company’s ability to continue as going concern, with respect to the consolidated and combined financial statements of Felicitex Therapeutics, Inc. as of December 31, 2021 and 2020 and for the years then ended. We also consent to the reference of our firm under the heading “Experts” in this Registration Statement.
/s/ Friedman LLP
Marlton, New Jersey
August 10, 2022